Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eberconazole→

Eberconazole PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
128326-82-9
Molecular formula
C18H14Cl2N2
Molecular weight
329.2 g/mol
Drug class
Topical imidazole antifungal
Mechanism of action
As an imidazole antifungal, eberconazole is understood to inhibit fungal ergosterol biosynthesis through interference with lanosterol 14α-demethylase, disrupting fungal cell-membrane integrity; the specific molecular contribution of each pathway has not been fully characterised in the cited clinical trial.
Indications / reported uses
  • Topical treatment of dermatophytoses
  • Topical use has also been reported for cutaneous candidiasis and pityriasis; exact indications depend on the locally authorised formulation

Sources: PubMed multicentre randomised trial — Eberconazole 1% cream for dermatophytosis · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical imidazole antifungal

Mechanism of action

As an imidazole antifungal, eberconazole is understood to inhibit fungal ergosterol biosynthesis through interference with lanosterol 14α-demethylase, disrupting fungal cell-membrane integrity; the specific molecular contribution of each pathway has not been fully characterised in the cited clinical trial.

General use cases

  • Topical treatment of dermatophytoses
  • Topical use has also been reported for cutaneous candidiasis and pityriasis; exact indications depend on the locally authorised formulation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Eberconazole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eberconazole Permitted Daily Exposure (PDE) report (the Eberconazole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eberconazole Occupational Exposure Limit (OEL) report (the Eberconazole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.